{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', 'Table 2', 'Snapshot Response and virologic failure rates in previous switch', 'studies', 'Week 48', 'Study', 'Treatment Arm', 'HIV-1 RNA <50', 'Virologic Failure', 'c/mL', '(HIV-1 RNA >50', 'c/mL)', 'SPIRITa,b', 'RPV/FTC/TDF', '89%', '8/317 (2.5%)', 'STRATEGY-PIC', 'QUAD', '94%', '2/290 (<1%)', 'PI + FTC/TDF', '87%', '2/139 (1%)', 'STRATEGY-NNRTId', 'QUAD', '93%', '3/290 (1%)', 'NNRTI + FTC/TDF', '88%', '1/143 (<1%)', 'SALTe', 'ATV/r+3TC', '77%', 'Not available', 'ATV/r+2NRTIs', '76%', 'Not available', 'OLEg', 'LPV/r+3TC', '88%', 'Not available', 'LPV/r+TDF/FTC or ABC/3TC', '87%', 'Not availableh', 'GS-292-0109i', 'E/C/F/TAF', '97%', '10/959 (1%)', 'TDF-based regiment', '93%', '6/477 (1%)', 'GS-US-311-1089K', 'TAF containing regimen', '94%', '1/333 (<1%)', 'TDF regimen', '93%', '5/330 (2%)', 'SWORD1 & 2 (Overall)', 'DTG + RPV', '95%', '3/513(<1%)', 'CAR', '95%', '6/511 (1%)', 'SWORD1 & 2 (Female)', 'DTG + RPV', '93%', '1/120 (<1%)', 'CAR', '91%', '3/108 (2.8%)', 'STRIIVING\"', 'Early Switch DTG + ABC/3TC STR', '80%', '1/275 (<1%)', 'Late Switch DTG + ABC/3TC STR', '91%', '3/244 (1%)', 'GS-US-380-1844', 'BIC/TFC/TAF', '94%', '3/282(1.1%)', 'ABC/DTG/3TC', '95%', '1/282(<1%)', 'GS-US-380-1878\u00b0', 'BIC/F/TAF', '92%', '5/290(1.7%)', 'Current Regimen (Boosted ATV or', '89%', '5/287(1.7%)', 'DRV plus FTC/TDF or ABC/3TC)', 'TANGOP', 'DTG/3TC', '93%', '1/369 (<1%)', 'TAF-based regimen (TBR)', '93%', '2/372 (<1%)', 'Week 24', 'STRIIVINGm', 'DTG + ABC/3TC STR', '85%', '3/275 (1%)', 'Current ART', '88%', '4/278 (1%)', 'BRAAVE20209', 'BIC/F/TAF QD', '96%', '2/328 (<1%)', 'Stay on baseline regimen (SBR)', '95%', '3/165 (2%)', 'E/C/F/TAF - elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide', 'a.', '[Palella, 2014]', 'b.', 'Participants in the Pl/r +2 NRTIs arm were switched to RPV/FTC/TDF at Week 24; therefore Week 48 response', 'data are not available for this treatment group.', 'C.', '[Arribas, 2014]', 'd.', '[Pozniak, 2014]', 'e.', '[Perez-Molina, 2015]', 'f.', 'The percentage of snapshot virologic failure is not available; however,4%in the 2-drug arm and 3% in the cART', 'arm had protocol defined virologic failure (PDVF).', 'g.', '[Arribas, 2015]', 'h. The percentage of snapshot virologic failure is not available; however, 2% per arm had PDVF.', 'i.', '[Mills, 2016]', 'j.', 'Elvitegravir (EVG)/Cobistat/TDF/FTC, EFV/TDF/FTC, ATV/Cobistat/TDF/FTC, or RTV/ATV/TDF/FTC', 'k.', '[Gallant, 2016]', 'I.', '[Llibre, 2017]', '71']['2017N331008_06', 'CONFIDENTIAL', '208090', 'm.', '[Trottier, 2015]', 'n.', '[Molina, 2018]', 'o.', '[Daar, 2018]', 'p.', '[van Wyk, 2020]', 'q.', '[Hagins, 2020]', '72']\n\n###\n\n", "completion": "END"}